menu
    • menu

    Company profile for BioVersys AG

    NEW Drugs in Dev: 7
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it will be possible to restore the efficacy of established antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening...
    The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it will be possible to restore the efficacy of established antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening bacterial infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioVersys AGSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hochbergerstrasse 60c c/o Technologiepark CH-4057 Basel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bioversys.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bioversys-ag
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/bioversys?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioVersys Doses First Patient in Phase 2b AlpE Pulmonary TB Trial
    BioVersys Doses First Patient in Phase 2b AlpE Pulmonary TB Trial

    13 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254275/0/en/BioVersys-Announces-First-Patient-Dosed-in-Phase-2b-Clinical-Trial-of-AlpE-in-Pulmonary-Tuberculosis.html

    GLOBENEWSWIRE
    13 Mar 2026
    Share Share
    BioVersys Reports 2025 Results, Provides Update and Hosts Call
    BioVersys Reports 2025 Results, Provides Update and Hosts Call

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3249840/0/en/BioVersys-to-Report-Its-Full-Year-2025-Financial-Results-Provide-a-Business-Update-and-Host-a-Conference-Call.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Bioversys Initiates BV100 Phase 3 Trial, Issues Business Update
    Bioversys Initiates BV100 Phase 3 Trial, Issues Business Update

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203614/0/en/BioVersys-Announces-BV100-Phase-3-Initiation-and-Provides-a-Business-Update.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Bioversys Reveals Key Financials and Highlights for H1 2025
    Bioversys Reveals Key Financials and Highlights for H1 2025

    10 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/10/3147471/0/en/Bioversys-Reports-Corporate-Highlights-and-Key-Financials-For-the-First-Half-2025.html

    GLOBENEWSWIRE
    10 Sep 2025
    Share Share
    Bioversys to Release First-Half 2025 Financial Results
    Bioversys to Release First-Half 2025 Financial Results

    29 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-29/bioversys-to-announce-its-first-half-2025-financial-results-provide-a-business-update-and-host-a-co

    PHARMAWEB
    29 Aug 2025
    Share Share
    BioVersys Granted EMA Orphan Status for Alpibectir & Ethionamide
    BioVersys Granted EMA Orphan Status for Alpibectir & Ethionamide

    27 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/27/3139705/0/en/BioVersys-Receives-EMA-Orphan-Designation-for-the-Combination-of-Alpibectir-and-Ethionamide-for-the-Treatment-of-Tuberculosis.html

    GLOBENEWSWIRE
    27 Aug 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search